Extrapulmonary tuberculosis in patients with RET fusion-positive non-small cell lung cancer treated with pralsetinib: A Korean single-centre compassionate use experience
-
Published:2021-12
Issue:
Volume:159
Page:167-173
-
ISSN:0959-8049
-
Container-title:European Journal of Cancer
-
language:en
-
Short-container-title:European Journal of Cancer
Author:
Lee Yong-Pyo,
Jeong Byeong-Ho,
Eun YeongheeORCID,
Kang Cheol-In,
Park Sehhoon,
Jung Hyun Ae,
Lee Se-Hoon,
Ahn Jin SeokORCID,
Ahn Myung-Ju,
Park Keunchil,
Sun Jong-Mu
Subject
Cancer Research,Oncology
Reference23 articles.
1. RET gene fusions in malignancies of the thyroid and other tissues;Santoro;Genes,2020
2. Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study;Gainor;Lancet Oncol,2021
3. Activity and tolerability of BLU-667, a highly potent and selective RET inhibitor, in patients with advanced RET-altered thyroid cancers;Taylor;J Clin Oncol,2019
4. Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study;Subbiah;Lancet Diabetes Endocrinol,2021
5. RECIST 1.1-update and clarification: from the RECIST committee;Schwartz;Eur J Cancer,2016
Cited by
8 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献